EGFR and melanoma: Likewise, in the context of targeted therapies, increased oxidative stress is observed in melanoma cells resistant to BRAF inhibition [70], while autophagy supports drug resistance against EGFR-targeted therapies in EGFR-driven cancer cells [71].